Rejuvenation Technologies

What Rejuvenation Technologies does

Rejuvenation Technologies is a private, preclinical biotechnology company developing modified-mRNA therapeutics that temporarily activate telomerase to extend telomeres in specific cells. The company's platform centers on a nucleoside-modified mRNA encoding TERT (telomerase reverse transcriptase), delivered via proprietary lipid nanoparticles to targeted tissues, with the goal of reversing cellular aging at the chromosomal level while avoiding the cancer risks associated with permanent telomerase activation. Three therapeutic candidates are in preclinical development: TeloAT2 for pulmonary fibrosis, TeloHep for chronic liver disease, and TeloHSC for hematologic indications including bone marrow failure, each supported by Phase I trials planned in Australia.

The company holds more than 40 granted patents and traces its scientific foundation to the 2015 FASEB Journal publication by Stanford-affiliated researchers, including co-founder Dr. Helen Blau, who established the role of short telomeres in monogenic diseases. Rejuvenation Technologies is led by Stanford PhD co-founders John Ramunas (CEO) and Glenn Markov (COO), with clinical leadership including a part-time Chief Medical Officer and a Director of Clinical Development who previously led the FDA approval of pirfenidone. The Scientific Advisory Board includes KOLs in telomere-driven pulmonary fibrosis from Stanford and Columbia.

The business model is a traditional pharmaceutical development and commercialization path. Rejuvenation Technologies is pre-revenue and currently generates no product sales; revenue is expected to materialize only after regulatory approval and subsequent launch through healthcare providers and pharmacies. To date, the company has raised approximately $15.2 million in disclosed funding, including a $10.6 million seed round led by Khosla Ventures in September 2023, over $8 million in grant funding since 2023, and a $2 million round in March 2025. Other investors include Y Combinator, Asymmetry Ventures, LifeSpan Vision Ventures, Longevitytech.fund, Shanda Group, and Merchant Adventures. The company has engaged the FDA on its telomere extension programs and is pursuing clinical development through accelerated regulatory pathways for rare-disease indications.

Name

Rejuvenation Technologies

Legal name

Rejuvenation Technologies Inc.

Website

https://www.rejuvenationtech.com/

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Rejuvenation Technologies is a preclinical biotech developing modified-mRNA therapeutics that temporarily activate telomerase to extend telomeres, with three candidates (TeloAT2, TeloHep, TeloHSC) targeting pulmonary fibrosis, chronic liver disease, and hematologic disorders.

Ownership category

akta.pro rank

Product category

mRNA Telomere Extension Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

akta.pro secondary industries

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

Keywords

• MRNA therapeutics
• Telomere extension
• Biopharmaceutical research
• Cellular aging therapies
• Lipid nanoparticle delivery

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Therapeutic Product Revenue: Pre-revenue biotech company developing mRNA-based therapeutics. Expected to generate revenue through FDA-approved treatments for aging-related diseases including pulmonary fibrosis, liver disease, and hematologic conditions. Revenue model will be traditional pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Rejuvenation Technologies develops mRNA-based therapeutics that use modified mRNA encoding TERT (telomerase reverse transcriptase), delivered via proprietary lipid nanoparticles, to temporarily activate telomerase and safely lengthen telomeres in specific cells. Its pipeline includes three preclinical therapeutic candidates — TeloAT2 for pulmonary fibrosis, TeloHep for chronic liver disease, and TeloHSC for hematologic conditions — targeting diseases caused by telomere shortening. The company is pre-revenue and engaged with the FDA, with Phase I trials planned in Australia.

Product overview

Rejuvenation Technologies is developing a platform of mRNA-based telomerase activation therapeutics for treating diseases caused by telomere shortening. The core technology uses modified mRNA encoding TERT (telomerase reverse transcriptase) delivered via proprietary lipid nanoparticles to temporarily activate telomerase and safely lengthen telomeres in specific cells. The product portfolio includes three therapeutic candidates: TeloAT2 for pulmonary fibrosis, TeloHep for chronic liver disease, and TeloHSC for hematologic conditions. All three programs share the same modified mRNA telomerase activation platform and targeted lipid nanoparticle delivery technology.

Differentiator

Problem solved

Functional benefit

Products and services

• TeloAT2
• TeloHep
• TeloHSC

Quantifiable outcome

• Over 5 years of telomere shortening reversed in 1 day in preclinical studies
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and major.

• Helen Blau (Stanford University)coreStrategic or Co-development PartnerDr. Helen Blau, Professor at Stanford University, is a co-inventor and Scientific Advisory Board Founder & Advisor. She discovered that short telomeres underlie the fatal etiology of multiple monogenic diseases, providing foundational scientific expertise and intellectual property to the company.
• Christine Kim Garcia (Columbia University)majorStrategic or Co-development PartnerDr. Christine Kim Garcia, MD, PhD, Chief of Pulmonary, Allergy and Critical Care Medicine and Professor of Medicine at Columbia University Irving Medical Center, serves as Scientific Advisor. She is a Key Opinion Leader (KOL) on the role of short telomeres in pulmonary fibrosis, supporting clinical development strategy.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Translate Bio (Sanofi): Translate Bio, acquired by Sanofi, developed mRNA therapeutics for cystic fibrosis and other rare diseases using lipid nanoparticle delivery. It is a direct peer to Rejuvenation Technologies on the mRNA-LNP rare-disease modality, though its therapeutic targets differ from telomere biology.
• TA Sciences / Telome Health: TA Sciences and Telome Health operate in telomere biology — TA Sciences in telomere-length nutraceutical/diagnostic products and Telome Health in telomere diagnostics. They are direct thematic peers to Rejuvenation Technologies on telomere biology commercialization, though they target consumer/diagnostic markets rather than therapeutic mRNA delivery.
• Arcturus Therapeutics: Arcturus is a clinical-stage mRNA medicines company developing self-amplifying and conventional mRNA therapeutics with proprietary lipid-mediated delivery. It is a direct peer to Rejuvenation Technologies in mRNA modality, LNP delivery, and rare-disease therapeutic focus, though its pipeline targets infectious disease and ornithine transcarbamylase deficiency rather than telomere biology.
• Acuitas Therapeutics: Acuitas Therapeutics specializes in lipid nanoparticle delivery systems for nucleic acid therapeutics, including mRNA, and supplies LNP technology to multiple mRNA vaccine and therapeutic developers. It is a direct comparable to Rejuvenation Technologies on the proprietary LNP delivery layer of the platform.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam is the leading RNAi therapeutics company with proprietary GalNAc and LNP delivery platforms for nucleic acid medicines. It is a broad incumbent comparable to Rejuvenation Technologies on the nucleic-acid-based therapeutic and targeted-delivery approach, though it targets liver-directed gene silencing rather than mRNA-encoded protein therapy.
• BioNTech: BioNTech is a major mRNA therapeutics company with a pipeline spanning immuno-oncology, infectious disease, and regenerative medicine. It is directly comparable to Rejuvenation Technologies on the mRNA modality and LNP delivery, but operates at much greater scale and with multiple clinical-stage assets.
• Moderna: Moderna is the leading clinical-stage mRNA therapeutics platform company with established LNP delivery technology and large-scale manufacturing. It is comparable to Rejuvenation Technologies as a fellow mRNA therapeutic developer, though it operates across infectious disease, oncology, and rare diseases with substantially greater resources and pipeline breadth.
• Altos Labs: Altos Labs is a well-funded cellular rejuvenation biotech pursuing cellular reprogramming to reverse aging and age-related disease. It is a broad incumbent comparable to Rejuvenation Technologies on the cellular aging reversal thesis, though Altos pursues a different biological mechanism (Yamanaka factors) versus telomere extension.
• Calico Life Sciences: Calico Life Sciences (Alphabet-backed) is a longevity and aging-focused biotech with significant R&D resources targeting fundamental mechanisms of aging. It is a broad incumbent comparable to Rejuvenation Technologies on the anti-aging therapeutic thesis, though Calico operates across multiple modalities rather than a single mRNA platform.

Emerging players

• Turn Biotechnologies: Turn Biotechnologies is an early-stage company developing mRNA-based cellular reprogramming therapies for age-related diseases. It is an emerging player comparable to Rejuvenation Technologies in the mRNA-rejuvenation modality and target disease areas, though Turn focuses on epigenetic reprogramming rather than telomere extension.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/rejuvenationtech
• LinkedInlinkedin.com/company/rejuvenation-tech

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds14 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rejuvenation Technologies